Eli Lilly's oral obesity drug Foundayo captures over 30% of new U.S. patients, challenging Novo Nordisk

Vardah Gill Tue, September 15, 2026 at 7:42 AM PDT | 5 min read

• LLY +0.67%
• NVO -1.85%

Eli Lilly and Company (NYSE: LLY) reports that its newly launched oral obesity drug, Foundayo, has captured more than 30% of new U.S. patients starting oral weight-loss medicines — a notable early gain against Novo Nordisk’s Wegovy pill.

According to Reuters, Wegovy initially held roughly 90% of the oral market. Lilly’s rapid share capture signals that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use.

The timing is strategically important for Lilly, as Foundayo was only launched in the U.S. in April 2026. The drug starts at $149 per month for self-pay patients and can cost as little as $25 for eligible commercially insured patients. Medicare beneficiaries can access it through the GLP-1 Bridge program at $50 per month.

Lilly’s SEC filing notes that Mounjaro and Zepbound already represented 65% of its revenue in the first six months of 2026, highlighting both the importance of the incretin franchise and the opportunity for Foundayo to broaden Lilly’s cardiometabolic revenue base.

Early Foundayo Momentum Could Extend Lilly’s GLP-1 Leadership

The strongest bullish implication is that Foundayo appears to be overcoming the biggest behavioral barrier in obesity treatment: patients’ preference for an oral medicine over an injection. Capturing more than 30% of new oral patients only months after launch suggests Lilly is establishing meaningful competitive positioning before the oral GLP-1 market fully scales.

Foundayo’s formulation also offers a practical advantage: it can be taken at any time of day without food or water restrictions. Lilly’s clinical data from the ATTAIN-1 trial showed an average 27.3-pound (12.4%) weight reduction at the highest dose among patients who remained on treatment.

The commercial opportunity could become considerably larger if Foundayo gains indications beyond obesity. In the ACHIEVE-3 trial, Foundayo produced:

• A 57.1% greater relative reduction in A1C
• A 73.6% greater relative reduction in body weight

...compared with oral semaglutide 14 mg. Lilly has submitted Foundayo for type 2 diabetes in the U.S., EU, and Japan, potentially expanding the addressable market beyond weight management.

The early oral-market traction also complements Lilly’s existing injectable franchise rather than simply cannibalizing it. A Lilly trial found that:

• Patients switching from maximum-tolerated Wegovy to Foundayo maintained all but 0.9 kg of their previous weight loss after one year.
• Patients switching from maximum-dose Zepbound to Foundayo maintained all but 5.0 kg.

This suggests Foundayo could serve as a maintenance or lower-burden treatment within Lilly’s broader obesity portfolio, increasing lifetime value per patient rather than limiting the opportunity to new prescriptions.

Foundayo’s Early Share Gain Faces Pricing and Competitive Risks

The key risk is that the reported 30%-plus share represents new patients in the oral category, not the overall obesity-drug market. Foundayo still has to prove that its early prescription momentum can translate into sustained volume, long-term adherence, and meaningful revenue.

Novo’s Wegovy pill started with approximately 90% of new oral patients, so Lilly’s gain is encouraging. However, the competitive landscape is changing rapidly. Novo is already studying lower-dose versions of its pill that could improve affordability, tolerability, and treatment flexibility.

Pricing could also pressure the economic value of the market as competition intensifies. Lilly has introduced Foundayo at relatively low access prices, including:

• $25 for some commercially insured patients
• $50 through the Medicare Bridge program

If Lilly and Novo compete aggressively for share through discounts and payer concessions, prescription growth could translate into thinner margins.

Story Continues